Status:
NOT_YET_RECRUITING
Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabe...
Detailed Description
Investigators will conduct a single-center clinical trial at Labafinezhad Hospital in Tehran, Iran. Initially, 15 stable chronic kidney failure patients with a glomerular filtration rate \< 30 cc/min ...
Eligibility Criteria
Inclusion
- age ≥18 years and history of diabetes or BMI over 27
Exclusion
- Previous usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and/or nonadherence to tirzepatide therapy
Key Trial Info
Start Date :
February 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT07176663
Start Date
February 1 2026
End Date
May 1 2026
Last Update
December 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nooshin Dalili
Tehran, Iran, 1666663421